115 related articles for article (PubMed ID: 9776187)
1. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial.
Gleich LL; Gluckman JL; Armstrong S; Biddinger PW; Miller MA; Balakrishnan K; Wilson KM; Saavedra HI; Stambrook PJ
Arch Otolaryngol Head Neck Surg; 1998 Oct; 124(10):1097-104. PubMed ID: 9776187
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Stopeck AT; Hersh EM; Akporiaye ET; Harris DT; Grogan T; Unger E; Warneke J; Schluter SF; Stahl S
J Clin Oncol; 1997 Jan; 15(1):341-9. PubMed ID: 8996161
[TBL] [Abstract][Full Text] [Related]
5. Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI; Selk LM; Vogelzang NJ
Clin Cancer Res; 1999 Oct; 5(10):2766-72. PubMed ID: 10537340
[TBL] [Abstract][Full Text] [Related]
7. Technology evaluation: Allovectin-7, Vical.
Galanis E
Curr Opin Mol Ther; 2002 Feb; 4(1):80-7. PubMed ID: 11883699
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
Bergen M; Chen R; Gonzalez R
Expert Opin Biol Ther; 2003 Apr; 3(2):377-84. PubMed ID: 12662150
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility gene therapy: the importance of haplotype and beta 2-microglobulin.
Salamone FN; Gleich LL; Li YQ; Stambrook PJ
Laryngoscope; 2004 Apr; 114(4):612-5. PubMed ID: 15064612
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial.
Norman JA; Parker S; Lew D; Manthorpe M; Marquet M
Hum Gene Ther; 1995 May; 6(5):549-50. PubMed ID: 7578391
[No Abstract] [Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.
Belldegrun A; Tso CL; Zisman A; Naitoh J; Said J; Pantuck AJ; Hinkel A; deKernion J; Figlin R
Hum Gene Ther; 2001 May; 12(8):883-92. PubMed ID: 11387054
[TBL] [Abstract][Full Text] [Related]
14. Immunologic therapy targeting metastatic melanoma: allovectin-7.
Chowdhery R; Gonzalez R
Immunotherapy; 2011 Jan; 3(1):17-21. PubMed ID: 21174553
[TBL] [Abstract][Full Text] [Related]
15. Alloantigen gene therapy for head and neck cancer: evaluation of animal models.
Gleich LL; Li YQ; Li S; Gluckman JL; Stambrook PJ
Head Neck; 2003 Apr; 25(4):274-9. PubMed ID: 12658731
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
Grandis JR; Falkner DM; Melhem MF; Gooding WE; Drenning SD; Morel PA
Clin Cancer Res; 2000 Jul; 6(7):2794-802. PubMed ID: 10914726
[TBL] [Abstract][Full Text] [Related]
17. [Antitumour study with combined IL-2 gene therapy and radiation for head and neck squamous cell carcinoma].
Liu S; Yang H; Tang Z; Liang C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 17(2):105-7. PubMed ID: 12833697
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
Gonzalez R; Hutchins L; Nemunaitis J; Atkins M; Schwarzenberger PO
Melanoma Res; 2006 Dec; 16(6):521-6. PubMed ID: 17119453
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.
Rubin J; Galanis E; Pitot HC; Richardson RL; Burch PA; Charboneau JW; Reading CC; Lewis BD; Stahl S; Akporiaye ET; Harris DT
Gene Ther; 1997 May; 4(5):419-25. PubMed ID: 9274718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
